Loading stock data…
PTC Therapeutics (PTCT)
$81.57-2.86 (-3.39%)
After Hours$81.58+0.01 (+0.01%)· Last close Jun 29
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PTC Therapeutics, Inc. in the Healthcare sector is trading at $81.97 with a market capitalization of $6.2B. Wall Street consensus targets $93.93 (14 analysts), implying a +14.6% move over the next 12 months. The stock is currently near its 52-week high of $87.50, remaining 15.4% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $272.55M↑ | $164.68M↓ | $211.01M↑ | $178.88M↓ | $1.18B |
| Gross Profit | $244.52M↑ | $157.73M↓ | $195.23M↑ | $167.46M↓ | $1.16B |
| Operating Income | $45.89M↑ | -$81.62M↓ | $3.49M↑ | -$34.86M↓ | $969.50M |
| Net Income | -$2.81M↑ | -$134.97M↓ | $15.90M↑ | -$64.85M↓ | $866.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
103.47%
Volume
Today's trading volume
4.26M
Recent News
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
This Biotech Stock Is Surging 81% on Surprise Good News From FDA
Gene therapy company uniQure has faced a brutal uphill battle to commercialize its experimental treatment for Huntington’s disease, but its outlook suddenly has brightened. Shares of the Amsterdam-based biopharmaceutical company rose 81% to $48.77 on Wednesday after uniQure said it would seek regulatory approval to bring its gene therapy candidate, AMT-130, to market. The gains put uniQure stock on pace for its highest close since October and its largest single-day percentage increase since September, according to Dow Jones Market Data.
Street Calls of the Week
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. InvestingPro subscribers always get first dibs on market-moving AI analyst comments. Upgrade today! Crox *TLDR: Baird boosts Crocs target on strong turnaround momentum. What’s the full story? Baird steps off the sidelines, upgrading Crocs Inc (NASDAQ:CROX) to Outperform and slapping on a $150 price target. For months, the team played it safe, spooked by a brutal retail climate and a looming
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls